Monday, July 26, 2021
HomeLatest Pharma-NewsUSFDA Approved GIVLAARI(givosiran) for the Treatment of Adults with Acute Hepatic...

USFDA Approved GIVLAARI(givosiran) for the Treatment of Adults with Acute Hepatic Porphyria

Nov. 20, 2019: Alnylam Pharmaceuticals, the leading RNAi therapeutics company, announced  the USFDA approved GIVLAARI (givosiran) injection (subcutaneous) for the treatment of adults with acute hepatic porphyria (AHP).

AHP is an exceptional, genetic diseases characterized by devitalizing, potentially life-threatening attacks and, for some patients, chronic manifestations that depressingly impact daily performance and quality of life.

- Advertisement -

Long-standing complications of AHP are chronic neuropathic pain, chronic kidney disease, hypertension and liver disease. GIVLAARI reduces the rate of porphyria attacks that required hospitalizations, urgent healthcare visits or IV hemin administration at home. http://investors.alnylam.com/news-releases/news-release-details/alnylam-announces-approval-givlaaritm-givosiran-us-food-and-drug

LEAVE A REPLY

Please enter your comment!
Please enter your name here

11 + 15 =

- Advertisment -

Most Popular